Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm, a biopharmaceutical company, has signed a cooperative R&D agreement with the National Institute of Neurological Diseases and Stroke, a part of the National Institutes of Health for research on a therapeutic agent for untreatable brain diseases in humans.
Subscribe to our email newsletter
Under the terms of the cooperative R&D agreement, National Institute of Neurological Diseases and Stroke (NINDS) will deliver NeoPharm’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (IL-13), in conjunction with a surrogate marker via NINDS’s patented methodology of convection enhanced delivery, which was previously licensed to NeoPharm.
The company will provide both the drug and technical resources to study its effects in various brain cancers in humans.
Laurence Birch, president and CEO of NeoPharm, said: “This cooperative R&D agreement serves as another step in pursuing the validation of IL-13’s impact on possibly increasing and enhancing the life span of patients diagnosed with terminal brain cancers.”